ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IBO vs EDSA // FREE CASH FLOW YIELD

Impact BioMedical Inc. (NYSE) VS. Edesa Biotech Inc. (NASDAQ) • 15-METRIC TALLY: IBO 5 — EDSA 0
▲ FREE CASH FLOW YIELD LEADER: IBO
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBO VS. EDSA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IBO EDSA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin -30.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -27.50% -35.00% +7.50 IBO /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -5.72% -20.08% +14.36 IBO /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.88 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 1/9 +1.00 IBO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.2 32.4 +14.80 IBO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $34.3M $32.9M $1.3M IBO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IBO REV EDSA REV IBO GROSS % EDSA GROSS % IBO FCF EDSA FCF
FY 2025 $32.0K $22.2M -50.0% — -$1.9M -$7.3M
FY 2024 $80.5M $19.6M — — -$2.9M -$4.9M
FY 2023 $11.3M $25.8M — — -$2.9M -$6.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBO // BETA —
EDSA // BETA —